Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
How Merit compares to the two alternatives most research buyers consider for Retatrutide
In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: 3Q 2025 the first GLP-1 (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction 4Q 2025 Wegovy for heart failure with preserved ejection fraction and obesity October 2025 new indication for oral Rybelsus for secondary CV risk reduction 2025 Ozempic for T2DM and peripheral artery disease (PAD) Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape
Fever or jaundice (yellowing of the skin or eyes)
These medications carry a boxed warning about thyroid C-cell tumors observed in rodent studies and are contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Otto Sipe CEO, Photon *Please note: this is an Aprils Fool joke, and thus, it is not a real announcement
00Namechange00 18/01/2025 07:52 Of course they are a scam and they are making illicit claims
